S 221237
Alternative Names: OPM-201; S-221237Latest Information Update: 23 Apr 2024
At a glance
- Originator Oncodesign Biotechnology
- Developer Servier
- Class Antiparkinsonians; Macrocyclic compounds; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease